Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
g39hFFMdTE4p87AJ
